Comparative Pharmacology
Head-to-head clinical analysis: EXNA versus ZESTORETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXNA versus ZESTORETIC.
EXNA vs ZESTORETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI): inhibits serotonin (5-HT) reuptake at the presynaptic neuron, increasing serotonin availability in the synaptic cleft.
Combination of lisinopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic). Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, increasing diuresis and reducing plasma volume.
EXNA is not a recognized drug; no standard dosing available.
Zestoretic (lisinopril/hydrochlorothiazide) is available in fixed-dose combinations. Typical adult dose: 10 mg/12.5 mg, 20 mg/12.5 mg, or 20 mg/25 mg orally once daily. Maximum dose: lisinopril 80 mg/day, hydrochlorothiazide 50 mg/day.
None Documented
None Documented
Terminal elimination half-life 12-18 hours (mean 14 h) in adults; prolonged in renal impairment (up to 30-40 h in CrCl <30 mL/min).
Lisinopril: terminal half-life approximately 12 hours (accumulation half-life 13.8 hours in patients with normal renal function). Hydrochlorothiazide: terminal half-life 5.6–14.8 hours (mean 9.6 hours).
Primarily renal (70% unchanged drug; 15% as metabolites); biliary/fecal (10%); <5% in breast milk.
Lisinopril is excreted unchanged in urine; 100% renal elimination. Hydrochlorothiazide is excreted primarily by the kidney (≥95% as unchanged drug) via tubular secretion.
Category C
Category C
Diuretic
ACE Inhibitor + Diuretic